Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance

Figures & data

Table 1.  Micelle formulations and characterization parameters.

Formulation code	Vitamin E	PTX amount (% of polymer weight)	ELC amount (theoretical final concentration, µM)	Particle size (nm, mean ± SD, n = 6)	PDI (mean ± SD, n = 6)
M1	+	5	25	25.48 ± 0.23	0.29 ± 0.011
M2	+	10	25	18.97 ± 0.08	0.28 ± 0.017
M3	-	5	25	16.33 ± 0.37	0.022 ± 0.007
M4	-	10	25	16.31 ± 0.31	0.037 ± 0.030

Table 2.  Encapsulation efficiencies of the formulations.

	Formulation	Drug incorporated (%)	Drug amount per mL of micelles (µg)
PTX	M1	81.34 ± 11.46	115.5 ± 16.2
	M2	78.9 ± 9.7	224.3 ± 27.7
	M3	83.28 ± 2.52	118.2 ± 3.5
	M4	86.5 ± 0.58	245.6 ± 1.7
ELC	M1	27.42 ± 3.41	0.77 ± 0.069
	M2	NA	NA
	M3	23.2 ± 11.9	0.65 ± 0.33
	M4	50.9 ± 13.5	7.3 ± 1.7

Results were given as mean ± SD, n = 3.

Figure 1.  PTX release from PTX- and ELC-co-loaded micelles under sink conditions (n = 3, mean ± SD).

Figure 2.  Cytotoxicity of different formulations after 12 h towards MDCKII-parental cells. Error bars indicate mean ± SD, n = 6.

Figure 3.  Cytotoxicity of different formulations after 12 h towards MDCKII-MDR1 cells. Error bars indicate mean ± SD, n = 6.